Celgene - Mark Alles
CAR-T therapy developer Celgene has named current President and COO Mark Alles as its new leader, replacing Bob Hugin from March 1.
Hugin has been at Celegene for almost 17 years and will serve as Executive Chairman, continuing to lead the Board of Directors and manage the strategic direction of the company.
"Bob Hugin is responsible for leading the transformation of Celgene into the global biopharmaceutical company that it is today," said Michael Casey, Celgene's Lead Independent Director. "As CEO, Bob has delivered exceptional results and we are incredibly grateful that Bob will continue to lead the strategic direction of Celgene."
Hugin commented on his successor, saying: "Mark is an extraordinary leader, whose knowledge of our business and commitment to patients have propelled the organization to incredible success."